Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sudeepta Aggarwal

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Leukocyte Biology|January 10, 2002
IL-17: prototype member of an emerging cytokine familySudeepta Aggarwal, Austin L Gurney
Blood|October 21, 2004
Human mesenchymal stem cells modulate allogeneic immune cell responsesSudeepta Aggarwal, Mark F Pittenger
The Journal of Biological Chemistry|November 6, 2002
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17Sudeepta Aggarwal, Nico Ghilardi, Ming-Hong Xie, et al.
Gynecologic Oncology|October 6, 2009
Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancerSudeepta Aggarwal, Tao He, William Fitzhugh, et al.
Journal of Clinical Pharmacology|September 26, 2023
Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID-19Ravi Shankar P Singh, Robert R LaBadie, Sima S Toussi, et al.
The British Journal of Dermatology|March 27, 2023
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group studyMegan N Landis, Stacy R Smith, Gabriel Berstein, et al.
The British Journal of Dermatology|August 20, 2022
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group studyMegan N Landis, Mark Arya, Stacy Smith, et al.
Diabetes|July 10, 2013
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of respondersKevan C Herold, Stephen E Gitelman, Mario R Ehlers, et al.
Blood|February 9, 2011
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphomaPaul A Moore, Wenjun Zhang, G Jonah Rainey, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trialStephen E Gitelman, Peter A Gottlieb, Mark R Rigby, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Leukocyte Biology|January 10, 2002
IL-17: prototype member of an emerging cytokine familySudeepta Aggarwal, Austin L Gurney
Blood|October 21, 2004
Human mesenchymal stem cells modulate allogeneic immune cell responsesSudeepta Aggarwal, Mark F Pittenger
The Journal of Biological Chemistry|November 6, 2002
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17Sudeepta Aggarwal, Nico Ghilardi, Ming-Hong Xie, et al.
Gynecologic Oncology|October 6, 2009
Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancerSudeepta Aggarwal, Tao He, William Fitzhugh, et al.
Journal of Clinical Pharmacology|September 26, 2023
Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID-19Ravi Shankar P Singh, Robert R LaBadie, Sima S Toussi, et al.
The British Journal of Dermatology|March 27, 2023
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group studyMegan N Landis, Stacy R Smith, Gabriel Berstein, et al.
The British Journal of Dermatology|August 20, 2022
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group studyMegan N Landis, Mark Arya, Stacy Smith, et al.
Diabetes|July 10, 2013
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of respondersKevan C Herold, Stephen E Gitelman, Mario R Ehlers, et al.
Blood|February 9, 2011
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphomaPaul A Moore, Wenjun Zhang, G Jonah Rainey, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trialStephen E Gitelman, Peter A Gottlieb, Mark R Rigby, et al.
Pageof 2